Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05043714 · ClinicalTrials.gov registry record · Phase 1
Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours
A Phase 1 study, sponsored by Akamis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05043714 is a Phase 1 study that has completed, run by Akamis Bio. The registered enrollment target is 30 participants.
The verdict
NCT05043714, a Phase 1 study, has completed, sponsored by Akamis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with nivolumab in patients with metastatic or advanced epithelial tumours and to determine the recommended dose of NG-641 in combination with nivolumab for further development in patients with metastatic or advanced epithelial tumours
Interventions
- BIOLOGICAL NG-641 in combination with Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-01 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05043714
The ClinicalTrials.gov registry entry for NCT05043714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akamis Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NG-641 in combination with Nivolumab is the first listed.
NCT05043714 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05043714 about?
NCT05043714 is a clinical study titled "Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours". This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-641 in combination with nivolumab (or standard of care PD-1 inhibition) in patients with metastatic or advanced epithelial tumours. The purpose is to characterize the safety and tolerability of NG-641 in combination with niv...
What is the current status of trial NCT05043714?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-12-01. Estimated completion is 2024-10-04.
What interventions are being tested in trial NCT05043714?
The interventions under investigation include: NG-641 in combination with Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05043714?
This trial is sponsored by Akamis Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.